Urgent surgery for RD gives best post-op VA

Article

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment, according to a recent study.

Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment (RD), according to a study in the Asia-Pacific Journal of Ophthalmology.

Researchers conducted a retrospective, noncomparative, interventional case series of 56 eyes with macula-on RD and 126 eyes with bullous macula-off RD.

When the duration of macula detachment was 2 days or less, approximately 90% of eyes achieved a postoperative 20/40 best-corrected visual acuity (BCVA). Between 2 and 10 days, the ratio of eyes achieving BCVA of 20/40 decreased (P = 0.008), plateauing around 40%. Mean BCVA showed a statistically significant decrease when the time from the RD to the vitrectomy/phacovitrectomy exceeded 10 days (P = 0.009).

"An increasing number of ophthalmologists are using vitrectomy as the first line of treatment for retinal detachment," the researchers said. "To achieve a good postoperative visual acuity, urgent surgery with a duration of macular detachment of 2 days or less is desired. Operative repair within this period, rather than outright emergency surgery, may be appropriate for most cases."

To view the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.